Brought to you by 
Astellas licenses GI candidate to new Drais virtual company Seldar
07 May 2013
Executive Summary
In a deal structured similarly to one formed between the firms two months ago, Astellas Pharma Inc. and Drais Pharmaceuticals Inc. will ally in the development and commercialization of Astellas’ Phase I bombesin BB2 receptor antagonist ASP7147 for irritable bowel syndrome with diarrhea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas licenses GI candidate to new Drais virtual company Seldar
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice